IM-250 is under clinical development by Innovative Molecules and currently in Phase I for Simplexvirus (HSV) Infections. According to GlobalData, Phase I drugs for Simplexvirus (HSV) Infections have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IM-250’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IM-250 overview
IM-250 is under development for the treatment of Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) induced diseases. The drug candidates act by targeting the helicase primase enzyme complex. It is administered through oral route.
Innovative Molecules overview
Innovative Molecules is a drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases. Innovative Molecules is headquartered in Munich, Germany.
For a complete picture of IM-250’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
